These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23564929)

  • 41. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
    Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the treatment of Kawasaki disease.
    Dominguez SR; Anderson MS
    Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of red blood cell distribution width for coronary artery lesions in patients with Kawasaki disease.
    Xu H; Fu S; Wang W; Zhang Q; Hu J; Gao L; Zhu W; Gong F
    Cardiol Young; 2016 Aug; 26(6):1151-7. PubMed ID: 26435202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Typical Kawasaki disease with atypical pneumonia: a paediatric case report.
    Maggio MC; Cimaz R; Failla MC; Dones P; Corsello G
    Scand J Rheumatol; 2021 May; 50(3):248-249. PubMed ID: 32804000
    [No Abstract]   [Full Text] [Related]  

  • 45. Chronic granulomatous disease associated with atypical Kawasaki disease.
    Yamazaki-Nakashimada MA; Ramírez-Vargas N; De Rubens-Figueroa J
    Pediatr Cardiol; 2008 Jan; 29(1):169-71. PubMed ID: 17676373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kawasaki disease shock syndrome: a severe form of Kawasaki disease.
    İşgüder R; Doksöz Ö; Bağ Ö; Ağın H; Meşe T; Karaarslan ÜU; Devrim İ
    Turk J Pediatr; 2013; 55(3):319-21. PubMed ID: 24217080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kawasaki disease: pathophysiology, clinical manifestations, and management.
    Dimitriades VR; Brown AG; Gedalia A
    Curr Rheumatol Rep; 2014 Jun; 16(6):423. PubMed ID: 24744086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment Options for Resistant Kawasaki Disease.
    Phuong LK; Curtis N; Gowdie P; Akikusa J; Burgner D
    Paediatr Drugs; 2018 Feb; 20(1):59-80. PubMed ID: 29101553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Length of hospital stay with prednisolone or cyclosporine for Kawasaki disease.
    Watanabe Y; Ikeda H; Watanabe T; Onuki Y; Iwaku T
    Pediatr Int; 2023; 65(1):e15673. PubMed ID: 38009989
    [No Abstract]   [Full Text] [Related]  

  • 52.
    Kwon YC; Kim JJ; Yun SW; Yu JJ; Yoon KL; Lee KY; Kil HR; Kim GB; Han MK; Song MS; Lee HD; Ha KS; Sohn S; Hong YM; Jang GY; Lee JK;
    Circ Genom Precis Med; 2018 Feb; 11(2):e002020. PubMed ID: 29453247
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT
    Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).
    ;
    Pediatr Int; 2014 Apr; 56(2):135-58. PubMed ID: 24730626
    [No Abstract]   [Full Text] [Related]  

  • 55. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids.
    Wright DA; Newburger JW; Baker A; Sundel RP
    J Pediatr; 1996 Jan; 128(1):146-9. PubMed ID: 8551407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Kawasaki disease shock syndrome: a case report].
    Vieni G; Pusceddu S; Bruno I; Ragni L; Marchetti F
    G Ital Cardiol (Rome); 2018 Feb; 19(2):111-114. PubMed ID: 29531383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kawasaki Disease.
    Newburger JW; Takahashi M; Burns JC
    J Am Coll Cardiol; 2016 Apr; 67(14):1738-49. PubMed ID: 27056781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
    Dhanrajani A; Yeung RSM
    Curr Opin Rheumatol; 2017 Sep; 29(5):547-552. PubMed ID: 28661936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases].
    Peyre M; Laroche C; Etchecopar C; Brosset P
    Arch Pediatr; 2013 Jul; 20(7):748-53. PubMed ID: 23693156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.